Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms

Authors

Luis F. Gonzalez-Mosquera, Hematology and Medical Oncology Department, Henry Ford Hospital, Detroit, MI, USA.
Bernard Moscoso, ESPOL Polytechnic University, Escuela Superior Politécnica del Litoral, ESPOL, Centro de Investigaciones Economicas, Guayaquil, Ecuador.
Pool Tobar, Advocate Aurora Health
Diana Cardenas-Maldonado, Department of Internal Medicine, Nassau University Medical Center, East Meadow, NY, USA.
Alida I. Podrumar, Department of Hematology and Oncology, Nassau University Medical Center, East Meadow, NY, USA.
Ruben Mesa, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA.
John A. Cuenca, Department of Critical Care Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Recommended Citation

Gonzalez-Mosquera LF, Moscoso B, Tobar P, et al. Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms [published online ahead of print, 2023 Mar 2]. Cancer Invest. 2023;1-20. doi:10.1080/07357907.2023.2187225

Affiliations

Advocate Illinois Masonic Medical Center

Abstract

We analyzed the National Inpatient Sample (NIS) database to study the sepsis-related outcomes in patients with Philadelphia negative myeloproliferative neoplasms (MPN). A total of 82,087 patients were included, most had essential thrombocytosis (83.7%), followed by polycythemia vera (13.7%), and primary myelofibrosis (2.6%). Sepsis was diagnosed in 15,789 (19.2%) patients and their mortality rate was higher than non-septic patients (7.5% vs 1.8%; P<.001). Sepsis was the most significant risk factor of mortality (aOR, 3.84; 95% CI, 3.51-4.21), others included liver disease (aOR, 2.42; 95% CI, 2.11-2.78), pulmonary embolism (aOR, 2.26; 95% CI, 1.83-2.80), cerebrovascular disease (aOR, 2.05; 95% CI, 1.81-2.33), and myocardial infarction (aOR, 1.73; 95% CI, 1.52-1.96).

Document Type

Article

PubMed ID

36862101